{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:08:51Z","timestamp":1785326931245,"version":"3.55.0"},"reference-count":52,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"unspecified","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011707","name":"PSP Association","doi-asserted-by":"publisher","award":["PSP 'Understood\u2019"],"award-info":[{"award-number":["PSP 'Understood\u2019"]}],"id":[{"id":"10.13039\/100011707","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/Y008219\/1"],"award-info":[{"award-number":["MR\/Y008219\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["MR\/Y008219\/1"],"award-info":[{"award-number":["MR\/Y008219\/1"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013128","name":"Multiple System Atrophy Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,7,22]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Existing evidence from cohort studies of atypical parkinsonism has demonstrated that median time from symptom onset to diagnosis is 3.4 years for progressive supranuclear palsy (PSP) and 3.1 years for multiple system atrophy (MSA). This compares to only 1.0\u20131.2 years in Parkinson\u2019s disease (PD). Earlier diagnosis is essential to facilitate recruitment to disease-modifying treatment trials. In the Early Assessment, Diagnosis and Treatment of Parkinsonism and Related Syndromes study, we will prospectively assess patients across the UK with incident parkinsonism and determine the best predictors to improve early diagnosis of the \u2018Parkinson-plus\u2019 syndromes (PPS) and build a trial-ready cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In this longitudinal prospective clinical cohort study, we will recruit 500 people with incident parkinsonism or syndromes associated with later PPS. Participants must be within 12 months of their first secondary care appointment for either motor disturbance or other symptoms of prodromes to PPS. Participants will return a self-completed questionnaire about their symptoms and have a structured neurological assessment by a clinician capturing key clinical features, clinical diagnostic criteria and quantitative clinical scales. Blood for DNA and plasma will be collected at baseline. 120 participants recruited to a subset of study sites will be invited to undergo detailed biomarker assessments such as additional blood collection, lumbar puncture, skin biopsy, MRI, cognitive assessments and digital biomarker assessments.<\/jats:p>\n                    <jats:p>We will stratify participants according to their most likely clinical diagnosis at 4 years post-baseline as the gold standard clinical diagnosis. This will be supplemented by neuropathological examination where available. We will use multivariable logistic modelling to identify early predictors of atypical PPS versus PD. Lifetime follow-up will be carried out using medical records linkage with participant consent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approvals have been granted by the Queen Square Research Ethics Committee (Ref: 14\/LO\/1575), with approval from the Health Research Authority and each participating site. Findings from the study will be published in academic journals and presented at UK-wide and international conferences, as well as disseminated via patient advocacy groups and charities including the PSP Association, Cure PSP, Rare Dementia Support and the MSA Trust.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-123017","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:45:34Z","timestamp":1785325534000},"page":"e123017","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Early assessment, diagnosis and treatment of Parkinsonism and Related Syndromes study (ExPRESS): a protocol for an observational study on incident parkinsonism"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4917-6559","authenticated-orcid":false,"given":"Riona Giulia","family":"Fumi","sequence":"first","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, University College London, London, UK"},{"name":"Movement Disorders Centre, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Caraiscos","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, University College London, London, UK"},{"name":"Movement Disorders Centre, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Jabbari","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, University College London, London, UK"},{"name":"Movement Disorders Centre, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1063-6937","authenticated-orcid":false,"given":"Timothy","family":"Rittman","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6648-3007","authenticated-orcid":false,"given":"Yoav","family":"Ben-Shlomo","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele T","family":"Hu","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huw R","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, University College London, London, UK"},{"name":"Movement Disorders Centre, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"2026072904452396000_16.7.e123017.1","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1498756","article-title":"Global, regional, national epidemiology and trends of Parkinson\u2019s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021","volume":"16","author":"Luo","year":"2024","journal-title":"Front Aging Neurosci"},{"key":"2026072904452396000_16.7.e123017.2","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2019","article-title":"Association of Parkinson\u2019s disease to Parkinson\u2019s plus syndromes, Lewy body dementia, and Alzheimer\u2019s dementia","volume":"7","author":"Prajjwal","year":"2024","journal-title":"Health Sci Rep"},{"key":"2026072904452396000_16.7.e123017.3","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26987"},{"key":"2026072904452396000_16.7.e123017.4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000525334","article-title":"Prevalence of Progressive Supranuclear Palsy and Corticobasal Syndrome in Scotland","volume":"56","author":"Swallow","year":"2022","journal-title":"Neuroepidemiology"},{"key":"2026072904452396000_16.7.e123017.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11791-2"},{"key":"2026072904452396000_16.7.e123017.6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/mdc3.13489","article-title":"Systematic Review of Prevalence Studies of Progressive Supranuclear Palsy and Corticobasal Syndrome","volume":"9","author":"Swallow","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"2026072904452396000_16.7.e123017.7","doi-asserted-by":"publisher","DOI":"10.1007\/S00415-019-09363-4"},{"key":"2026072904452396000_16.7.e123017.8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2022.5128","article-title":"Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries","volume":"80","author":"Logroscino","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026072904452396000_16.7.e123017.9","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.557","article-title":"Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade","volume":"6","author":"Takigawa","year":"2016","journal-title":"Brain Behav"},{"key":"2026072904452396000_16.7.e123017.10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827f0fd1"},{"key":"2026072904452396000_16.7.e123017.11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-328586"},{"key":"2026072904452396000_16.7.e123017.12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-307035"},{"key":"2026072904452396000_16.7.e123017.13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","article-title":"Neuropathology and molecular diagnosis of Synucleinopathies","volume":"16","author":"Koga","year":"2021","journal-title":"Mol Neurodegeneration"},{"key":"2026072904452396000_16.7.e123017.14","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29005"},{"key":"2026072904452396000_16.7.e123017.15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.neurol.2023.11.013","article-title":"Prevalence of multiple system atrophy: A literature review","volume":"180","author":"Kaplan","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"2026072904452396000_16.7.e123017.16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-022-00382-6","article-title":"Multiple system atrophy","volume":"8","author":"Poewe","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2026072904452396000_16.7.e123017.17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jamaneurol.2019.4347","article-title":"Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome","volume":"77","author":"Jabbari","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026072904452396000_16.7.e123017.18","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.571800","article-title":"Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database","volume":"12","author":"Viscidi","year":"2021","journal-title":"Front Neurol"},{"key":"2026072904452396000_16.7.e123017.19","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.637176","article-title":"Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy","volume":"12","author":"Kwasny","year":"2021","journal-title":"Front Neurol"},{"key":"2026072904452396000_16.7.e123017.20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.parkreldis.2022.01.004","article-title":"Prediagnostic Progressive Supranuclear Palsy - Insights from the UK Biobank","volume":"95","author":"Street","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"2026072904452396000_16.7.e123017.21","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1007\/s00415-023-11629-x","article-title":"The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson\u2019s disease (PD)","volume":"270","author":"Swallow","year":"2023","journal-title":"J Neurol"},{"key":"2026072904452396000_16.7.e123017.22","doi-asserted-by":"crossref","unstructured":"R\u00e4ty V , Kuusim\u00e4ki T , Majuri J , et al . Stability and Accuracy of a Diagnosis of Parkinson Disease Over 10 Years. Neurology 2025;104. doi:10.1212\/WNL.0000000000213499","DOI":"10.1212\/WNL.0000000000213499"},{"key":"2026072904452396000_16.7.e123017.23","first-page":"444","article-title":"Natural clinical course of progressive supranuclear palsy in Chinese patients in Hong Kong","volume":"25","author":"Shea","year":"2019","journal-title":"Hong Kong Med J"},{"key":"2026072904452396000_16.7.e123017.24","doi-asserted-by":"crossref","first-page":"117293","DOI":"10.1016\/j.jns.2020.117293","article-title":"Disease course and treatment patterns in progressive supranuclear palsy: A real-world study","volume":"421","author":"Morgan","year":"2021","journal-title":"J Neurol Sci"},{"key":"2026072904452396000_16.7.e123017.25","doi-asserted-by":"crossref","first-page":"e1168","DOI":"10.1212\/WNL.0000000000200861","article-title":"Diagnosing premotor multiple system atrophy: Natural history and autonomic testing in an autopsy-confirmed cohort: Natural history and autonomic testing in an autopsy-confirmed cohort","volume":"99","author":"Vichayanrat","year":"2022","journal-title":"Neurology"},{"key":"2026072904452396000_16.7.e123017.26","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf080"},{"key":"2026072904452396000_16.7.e123017.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-025-01157-y","article-title":"Refining the diagnostic accuracy of Parkinsonian disorders using metaphenomic annotation of the clinicopathological literature","volume":"11","author":"Massey","year":"2025","journal-title":"NPJ Parkinsons Dis"},{"key":"2026072904452396000_16.7.e123017.28","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/mds.30261","article-title":"Clinical Diagnosis of Progressive Supranuclear Palsy (PSP): A Clinicopathological Comparison of Patients with Confirmed PSP and Clinical Mimics","volume":"40","author":"Wrigley","year":"2025","journal-title":"Mov Disord"},{"key":"2026072904452396000_16.7.e123017.29","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlad025"},{"key":"2026072904452396000_16.7.e123017.30","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/mdc3.13990","article-title":"Total Patient Delay: A Comparison of Patient and Clinician\/Health System Delays in the Diagnosis of Progressive Supranuclear Palsy and Corticobasal Syndrome","volume":"11","author":"Swallow","year":"2024","journal-title":"Mov Disord Clin Pract"},{"key":"2026072904452396000_16.7.e123017.31","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1177\/1877718X241291996","article-title":"Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials","volume":"14","author":"Marchand","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"2026072904452396000_16.7.e123017.32","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jagp.2024.03.002","article-title":"Time to Diagnosis and Its Predictors in Syndromes Associated With Frontotemporal Lobar Degeneration","volume":"32","author":"Libri","year":"2024","journal-title":"Am J Geriatr Psychiatry"},{"key":"2026072904452396000_16.7.e123017.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-6905-3"},{"key":"2026072904452396000_16.7.e123017.34","doi-asserted-by":"crossref","unstructured":"Cervantes-Arriaga A , Sarabia-Tapia C , Esquivel-Zapata O , et al . Pitfalls and caveats in the diagnostic pathway of people with Parkinson\u00d3?s disease. RMN 2022;23. doi:10.24875\/RMN.21000041","DOI":"10.24875\/RMN.21000041"},{"key":"2026072904452396000_16.7.e123017.35","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/mds.28263","article-title":"Clinical Conditions \u201cSuggestive of Progressive Supranuclear Palsy\u201d-Diagnostic Performance","volume":"35","author":"Grimm","year":"2020","journal-title":"Mov Disord"},{"key":"2026072904452396000_16.7.e123017.36","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1212\/01.wnl.0000338701.59007.ee","article-title":"Early diagnosis of progressive supranuclear palsy","volume":"71","author":"Golbe","year":"2008","journal-title":"Neurology"},{"key":"2026072904452396000_16.7.e123017.37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40120-022-00420-1","article-title":"The Lived Experiences of People with Progressive Supranuclear Palsy and Their Caregivers","volume":"12","author":"Respondek","year":"2023","journal-title":"Neurol Ther"},{"key":"2026072904452396000_16.7.e123017.38","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"2026072904452396000_16.7.e123017.39","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004058"},{"key":"2026072904452396000_16.7.e123017.40","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1093\/brain\/awaf132","article-title":"Cognitive and neuropsychiatric profiles distinguish atypical parkinsonian syndromes","volume":"148","author":"Hu","year":"2025","journal-title":"Brain"},{"key":"2026072904452396000_16.7.e123017.41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006366"},{"key":"2026072904452396000_16.7.e123017.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-025-02148-2","article-title":"Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Parkinson\u2019s disease","volume":"8","author":"Gunter","year":"2025","journal-title":"NPJ Digit Med"},{"key":"2026072904452396000_16.7.e123017.43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mdc3.13413","article-title":"Eye Movement Disorders in Movement Disorders","volume":"9","author":"Kassavetis","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"2026072904452396000_16.7.e123017.44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/EB.S384769","article-title":"Detecting Abnormal Eye Movements in Patients with Neurodegenerative Diseases - Current Insights","volume":"16","author":"Sekar","year":"2024","journal-title":"Eye Brain"},{"key":"2026072904452396000_16.7.e123017.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2011.09.005"},{"key":"2026072904452396000_16.7.e123017.46","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-305277"},{"key":"2026072904452396000_16.7.e123017.47","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3233\/JPD-150662","article-title":"Tracking Parkinson\u2019s: Study Design and Baseline Patient Data","volume":"5","author":"Malek","year":"2015","journal-title":"J Parkinsons Dis"},{"key":"2026072904452396000_16.7.e123017.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.09.025"},{"key":"2026072904452396000_16.7.e123017.49","doi-asserted-by":"publisher","DOI":"10.1093\/BRAIN\/AWAD105"},{"key":"2026072904452396000_16.7.e123017.50","doi-asserted-by":"crossref","DOI":"10.3390\/genes16111302","article-title":"Association of Sporadic and Genetic Parkinson\u2019s Disease with Cancer: Insights from the PPMI Cohort","volume":"16","author":"Sfikas","year":"2025","journal-title":"Genes (Basel)"},{"key":"2026072904452396000_16.7.e123017.51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JPD-140523","article-title":"Parkinson\u2019s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort","volume":"5","author":"Lawton","year":"2015","journal-title":"J Parkinsons Dis"},{"key":"2026072904452396000_16.7.e123017.52","unstructured":"PSP Association . STATE of diagnosis for progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) report. 2023. Available: https:\/\/www.pspassociation.info\/wp-content\/uploads\/2023\/06\/PSPA_Diagnosis_Report_LR.pdf"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-123017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:45:41Z","timestamp":1785325541000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-123017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,29]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjopen-2026-123017"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-123017","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}